Management strategies for doxorubicin toxicity include dose adjustment, the use of cardioprotective agents like dexrazoxane, and regular cardiac monitoring. The development of liposomal formulations of doxorubicin has also been shown to reduce toxicity while maintaining efficacy. These formulations alter the drug's distribution, reducing its concentration in cardiac tissue.
